Rita Assi

Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology

Daniel A. Pollyea, Jessica K. Altman, Rita Assi et al. · Journal of the National Comprehensive Cancer Network · 2023 · 163 citations · Full text

Hematological Malignancy, Medicine, Acute Myeloid Leukemia +15

Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia

Rita Assi, Hagop M. Kantarjian, Nicholas J. Short et al. · Clinical Lymphoma Myeloma & Leukemia · 2017 · 159 citations

Tyrosine Kinase Inhibitor, Hematological Malignancy, Oncology +7

Final results of a phase 2, open‐label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome

Rita Assi, Hagop M. Kantarjian, Tapan M. Kadia et al. · Cancer · 2018 · 137 citations · Full text

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

Farhad Ravandi, Rita Assi, Naval Daver et al. · The Lancet Haematology · 2019 · 137 citations · Full text

Hematological Malignancy, Medicine, Mixed-phenotype Acute Leukemia +9

Impact of the variant allele frequency of <i>ASXL1</i>, <i>DNMT3A</i>, <i>JAK2</i>, <i>TET2</i>, <i>TP53</i>, and <i>NPM1</i> on the outcomes of patients with newly diagnosed acute myeloid leukemia

Koji Sasaki, Rashmi Kanagal‐Shamanna, Guillermo Montalban‐Bravo et al. · Cancer · 2019 · 93 citations